Clinical Trials Logo

Filter by:
NCT ID: NCT06361108 Not yet recruiting - Clinical trials for Diabetic Peripheral Neuropathic Pain

Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of YJ001 for Spray Use in Patients With Diabetic Peripheral Neuropathic Pain

Start date: April 10, 2024
Phase: Phase 1
Study type: Interventional

This Phase I, randomized, double-blind and placebo controlled study is to evaluate the safety, tolerability, and PK, and to preliminarily assess the efficacy of topically administered YJ001 in a multiple-ascending dose (MAD) fashion in the patients with DPNP. The study will be conducted at a single study center. In this study, 2 cohorts (N=24, 12 subjects for each cohort), each cohort will consist of 10 active and 2 placebo, with approximately equal numbers of male and female subjects. Each subject will be administered a single dose of YJ001 as multiple sprays topically on both feet and below the ankle in the morning on Day 1 and Day 2, and will be administered as twice daily doses once in the morning and the other in the evening (with an interval of 11 to 13 h) from Day 3 through Day 11.

NCT ID: NCT06255691 Not yet recruiting - Anxiety Clinical Trials

10-year Follow-up After Aortic Valve Replacement Surgery

AVR-10year
Start date: April 10, 2025
Phase:
Study type: Observational

There is a lack of data on patients self-reported outcomes (PROMs) on health-related quality of life (HRQoL)and symptoms on anxiety and depression 10 years after Surgical After Aortic Valve Replacement (SAVR), and patient reported experiences with the health services (PREMS). In this 10-years follow-up study on patients alive from the study named "The Impact of 24/ 7-phone Support on Readmission After Aortic Valve Replacement, a Randomized Clinical Trial (AVRre)" NCT02522663 we will repeat the survey on symtoms on anxiety and depresion using Hospital Anxiety and depression Scale (HADS), health-related quality of life (EQ-5D) and questions about experiences with the health services.

NCT ID: NCT03105596 Not yet recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

Start date: April 11, 2017
Phase: Phase 2
Study type: Interventional

This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL).

NCT ID: NCT05288543 Not yet recruiting - Atopic Dermatitis Clinical Trials

A Study of Orally Administered IPG7236 in Healthy Adult Participants

Start date: April 11, 2022
Phase: Phase 1
Study type: Interventional

The study is a phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetic and food effect of orally administered IPG7236 in healthy adult participants.

NCT ID: NCT05302128 Not yet recruiting - Clinical trials for Laparoscopic Cholecystectomy

The Effect of Cold Vapor on Nausea and Vomiting in the Early Postoperative Period After Laparoscopic Cholecystectomy

Start date: April 11, 2022
Phase: N/A
Study type: Interventional

Postoperative nausea and vomiting (PONV) was defined by the American Society of PeriAnesthesia Nurses (ASPAN) as nausea and/or vomiting in the first 24 hours after surgery and is among the most common complications after pain in patients undergoing surgery. PONV is divided into three as early, late, and delayed. Nausea-vomiting developing within 2-6 hours after surgery is classified as early, nausea-vomiting developing within 6-24 hours after surgery is classified as delayed, and nausea and/or vomiting developing within the first 24 hours after surgery are classified as delayed PONV. PONV increases the length of stay in the recovery room, delays starting oral intake, causes fluid and electrolyte imbalance, and causes pain, dehydration, delayed wound healing, decreased patient comfort, prolonged hospitalization, and increased cost. Therefore, the prevention and management of nausea and vomiting in the perioperative period in surgical patients are very important.

NCT ID: NCT05310162 Not yet recruiting - Clinical trials for Sleep Bruxism, Childhood

Effect of the Intervention "Food, Fun and Family" on Sleep Bruxism in Children

Start date: April 11, 2022
Phase: N/A
Study type: Interventional

Excess consumption of refined sugar and increased use of recreational screen time are risk factors for alterations in the quality of life that have been associated with sleep bruxism in children and that compromise the same mechanisms of alteration of the reward system in the brain. Therefore, the question of this research is: What is the effect of the Intervention "Food, Fun and Family (FFF)" on the frequency of sleep bruxism in children? The general objective of the research is to evaluate the effect of the Intervention "Food, Fun and Family (FFF)" on the frequency of sleep bruxism in 84 children who attend the pediatric dentistry postgraduate clinic of the CES University and the private consultation Dr. Claudia Restrepo and Dr. Adriana Santamaría. The frequency of sleep bruxism will be evaluated with the translated and validated Spanish version of the Children's Sleep Habits Questionnaire (CSHQ), which will be answered by the parents. The consumption of added sugar will be evaluated with the version translated into Spanish of the Health Behavior in School-Aged Children - Food-Frequency Questionnaire (HBSC-FFQ). The time on screens will be recorded through the parents' report, of the time in hours that the child spends using electronic media in a recreational way each weekday for a week and each weekend day for a week. A decrease in the frequency of sleep bruxism is expected to be found by reducing sugar consumption and screen time in the children evaluated. The results of this study will be presented at the IADR, ACFO, ACOP and CES University research meetings and will be published in a peer-reviewed scientific journal in category Q1.

NCT ID: NCT05313789 Not yet recruiting - Pain Clinical Trials

Analgesia Nociception Index for Pain Monitoring in Intensive Care Units

Start date: April 11, 2022
Phase:
Study type: Observational

The aim of this study is to examine the usability of ANI in patients who will be treated in intensive care unit.

NCT ID: NCT05318872 Not yet recruiting - Clinical trials for Head and Neck Neoplasms

Prospective Evaluation of ENDOSWIR Device Versus Pathology for Squamous Cell Carcinoma of Upper Aerodigestive Tract (ENDOSWIR-VADS)

ENDOSWIR-VADS
Start date: April 11, 2022
Phase:
Study type: Observational [Patient Registry]

A new medical optical device named ENDOSWIR is tested to determine its ability to determine if tissues are cancer or normal tissue on ex-vivo condition for specimen of ENT squamous cell cancers.

NCT ID: NCT05323669 Not yet recruiting - Thyroid Cancer Clinical Trials

Molecular Profile of Thyroid Nodules

MPTN
Start date: April 11, 2022
Phase:
Study type: Observational

Profiling and comparative analysis of genomic alterations and miRNA expression in benign and malignant thyroid tumors using histological and cytological specimens will be performed. Obtained information is necessary to create a molecular test to refine the cancer risk of cytologically indeterminate thyroid nodules.

NCT ID: NCT05333055 Not yet recruiting - Clinical trials for Diabetic Retinopathy

Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema

DRAGONS
Start date: April 11, 2022
Phase:
Study type: Observational

The DRAGONS study is a non-interventional, prospective study that will 1. characterize disease state biomarker (including cytokines, KKS metabolites, and cell adhesion molecules) levels from aqueous humor of subjects with various stages of diabetic retinopathy (DR) and diabetic macular edema (DME) as well as other retinal pathologies, and 2. correlate a broad array of aqueous humor disease state biomarkers with DR severity, DME anti-vascular endothelial growth factor (VEGF) responsiveness, and other retinal pathologies.